Zobrazeno 1 - 10
of 69
pro vyhledávání: '"Arie Barlev"'
Autor:
Crystal Watson, Dhanalakshmi Thirumalai, Arie Barlev, Eddie Jones, Sasha Bogdanovich, Kiren Kresa-Reahl
Publikováno v:
Neurology and Therapy, Vol 12, Iss 6, Pp 1961-1979 (2023)
Abstract Introduction Much of the current literature on treatment patterns and disability progression in multiple sclerosis (MS) does not distinguish between the relapsing–remitting and progressive subtypes (including primary [PPMS] and secondary p
Externí odkaz:
https://doaj.org/article/e5bed912d1c24028a5e2841dc4079259
Publikováno v:
Oncology and Therapy, Vol 8, Iss 2, Pp 299-310 (2020)
Abstract Introduction There are no validated patient-reported outcome (PRO) instruments for Epstein–Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD). The aim of this study was to assess the content applicability for three f
Externí odkaz:
https://doaj.org/article/a3f93ec3b29e41e18952e518600d4608
Autor:
Neil M. Schultz, Neal D. Shore, Simon Chowdhury, Laurence H. Klotz, Raoul S. Concepcion, David F. Penson, Lawrence I. Karsh, Hongbo Yang, Bruce A. Brown, Arie Barlev, Scott C. Flanders
Publikováno v:
BMC Urology, Vol 18, Iss 1, Pp 1-9 (2018)
Abstract Background This analysis estimated the number needed to treat with enzalutamide versus bicalutamide to achieve one additional patient with chemotherapy-naïve metastatic castration-resistant prostate cancer who would obtain clinical benefit
Externí odkaz:
https://doaj.org/article/ac2303e9cda546ff9696e315c7ef9767
Autor:
Neil M Schultz, Neal D Shore, Simon Chowdhury, Laurence H Klotz, Raoul S Concepcion, David F Penson, Lawrence I Karsh, Hongbo Yang, Bruce A Brown, Arie Barlev, Scott C Flanders
Publikováno v:
BMC Urology, Vol 18, Iss 1, Pp 1-1 (2018)
It has been highlighted that in the original article [1] there was a typesetting mistake in the Results – NNT in Strive section. This Correction article states the incorrect and correct sentence.
Externí odkaz:
https://doaj.org/article/9de2fcbbd4f74f6eb4c2185059fbb0ea
Autor:
Sridhar Chaganti, Arie Barlev, Sophie Caillard, Sylvain Choquet, Kate Cwynarski, Anke Friedetzky, Eva González-Barca, Natalia Sadetsky, Stefan Schneeberger, Dhanalakshmi Thirumalai, Pier L. Zinzani, Ralf U. Trappe
Publikováno v:
Advances in Therapy. 40:1267-1281
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3cafc17c8a9e6040715fee9a816f5156
https://doi.org/10.1007/s12325-022-02383-z
https://doi.org/10.1007/s12325-022-02383-z
Publikováno v:
Neurology and Therapy. 11:725-739
Fatigue is one of the most common and debilitating symptoms of multiple sclerosis (MS) but is challenging to assess and has not been comprehensively characterized in patients with progressive MS. This study aimed to (1) obtain qualitative evidence fr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::804e047e27f9f5791582766ec2cef39d
https://doi.org/10.1007/s40120-022-00337-9
https://doi.org/10.1007/s40120-022-00337-9
Publikováno v:
Journal of Medical Economics. 25:230-237
Aims\ud \ud Accurately estimating mean survival after solid organ transplant (SOT) is crucial for efficient healthcare resource allocation decisions. However, registry-based post-transplant recipient survival estimates vary greatly and are incomplete
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d78e92d8aed7b619833ce3da05f4ba4
https://doi.org/10.1080/13696998.2022.2033050
https://doi.org/10.1080/13696998.2022.2033050
Publikováno v:
Journal of drug assessment. 11(1)
A common chemotherapy regimen in post-transplant lymphoproliferative disease (PTLD) following solid organ transplants (SOT) is cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). This study reviews the quantitative evidence for long-te
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::898b330c439b3360a0b453bd6000c5c8
https://pubmed.ncbi.nlm.nih.gov/35693477
https://pubmed.ncbi.nlm.nih.gov/35693477
Publikováno v:
Oncology and Therapy
Oncology and Therapy, Vol 8, Iss 2, Pp 299-310 (2020)
Oncology and Therapy, Vol 8, Iss 2, Pp 299-310 (2020)
Introduction There are no validated patient-reported outcome (PRO) instruments for Epstein–Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD). The aim of this study was to assess the content applicability for three frequently
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac8d4e86f559f0be26e871b1e93179a9
https://doi.org/10.1007/s40487-020-00131-3
https://doi.org/10.1007/s40487-020-00131-3
Autor:
Bryn Thompson, Yoon Son Ahn, Crystal Watson, Melissa Skeans, Vikas R. Dharnidharka, Allyson Hart, Arie Barlev
Aims and Objectives: Patients diagnosed with post-transplant lymphoproliferative disease (PTLD) experience high mortality within the first 2 years of diagnosis; however, few data exist on the economic burden of PTLD in these patients. We determined t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eef8e791a0437319d1d7ba8ab67afa98
